Genitourinary Cancer, Prostate Cancer
Read Time: 3 mins

Maintaining Bone Health and Integrity During Androgen-deprivation Therapy for Prostate Cancer

Copy Link
Published Online: Aug 2nd 2011 US Oncological Review, 2008;4(1):50-4 DOI:
Authors: Thomas J Polascik
Quick Links:
Article Information

Since the early 1990s, earlier diagnosis and improved treatment options have caused a steady decline in the prostate cancer mortality rate.1,2 Consequently, many of the 186,000 men in the US who will be diagnosed with prostate cancer in 2008 may live for many years with the disease and any long-term treatment-related adverse effects (AEs).2

Since the early 1990s, earlier diagnosis and improved treatment options have caused a steady decline in the prostate cancer mortality rate.1,2 Consequently, many of the 186,000 men in the US who will be diagnosed with prostate cancer in 2008 may live for many years with the disease and any long-term treatment-related adverse effects (AEs).2
Androgen-deprivation therapy (ADT) has become an accepted standard of care for prostate cancer treatment and its use is recommended in various stages of the disease.3 However, ADT is not without AEs, some of which may have long-term consequences. Of particular concern is the increased risk for fracture associated with ADT, especially in patients treated for many years.4–6 Clinicians who treat prostate cancer patients should be aware of the potential AEs associated with ADT and of strategies for preventing and/or treating them. This article reviews the prevalence and consequences of bone loss and fractures in men with prostate cancer and without bone metastases receiving ADT, and discusses prevention and treatment strategies.
Adverse Effects Associated with Androgen-deprivation Therapy
Non-skeletal Adverse Effects
ADT-treated patients commonly experience a range of AEs, including sexual dysfunction, hot flashes, anemia, metabolic syndrome, body composition changes, fatigue, and cognitive and mood changes.7–10 Although the focus of this article is skeletal-related AEs, a brief discussion about the increased risk for cardiovascular disease (CVD) in patients receiving ADT is warranted to increase awareness of this potential long-term AE.8 ADT-associated AEs that can increase the risk for CVD include metabolic syndrome and body composition changes.3,8,9
Metabolic syndrome is diagnosed when three or more of the following are present: abdominal obesity, hypertriglyceridemia, low levels of high-density lipoprotein cholesterol, or elevated blood pressure. Low testosterone levels are predictive of the development of metabolic syndrome in men.3,8 Results of a recent cross-sectional study showed that 55% of prostate cancer patients receiving ADT for at least one year developed metabolic syndrome compared with 22% of age-matched eugonadal men not receiving ADT.8 The presence of metabolic syndrome in prostate cancer patients increases the risk for insulin resistance, diabetes mellitus, CVD, and death.3 Changes in body composition such as an increased proportion of body fat and/or weight gain are often observed in men receiving ADT, and also contribute to the risk for CVD.9 Compared with healthy controls, Chen and colleagues9 found that men receiving ADT for one to five years were 5.5 times more likely to become obese (body mass index [BMI] ≥30kg/m2). Prostate cancer patients are more likely to die from CVD than from prostate cancer itself, so clinicians should be aware of the increased CVD risk in all prostate cancer patients, especially those receiving ADT, and should monitor patients for early signs of CVD.11 Furthermore, before administering ADT to men with early-stage disease who are likely to receive long-term therapy (>1 year), clinicians must consider the risk for ADT-associated CVD, especially for men already at increased risk for CVD-related mortality.3

Skeletal Adverse Effects
Bone loss is the most studied ADT-associated AE. Results of multiple studies have shown that bone mineral density (BMD) of the femoral neck, lumbar spine, and total hip decreases by up to 4.6% annually in prostate cancer patients without bone metastases who receive ADT, a rate that is four to eight times higher than the normal bone loss rate (0.5–1% per year) observed in otherwise healthy aging men.1,10,12–21 As bone loss increases the probability of fracture, prostate cancer patients who receive ADT are at an increased risk for fracture and related morbidity and mortality.4–6,22 Indeed, men with prostate cancer and no bone metastases receiving ADT are up to 37% more likely to experience a fracture than patients not receiving ADT; fracture-related hospitalizations are also more common in patients receiving ADT compared with patients not receiving ADT (4.9 versus 2.2%; p<0.001).6 The personal and economic consequences of fractures are significant.
Studies evaluating the effects of ADT-related fractures on quality of life (QOL) are lacking, but results from studies that evaluate QOL in the general population indicate that QOL is substantially diminished in men who experience osteoporotic fractures.23
In one study, men who had experienced an osteoporotic hip fracture had decreased role-physical domain scores (a standard QOL measure) compared with men who had not experienced a fracture (-35.7; 95% confidence interval [CI] -60.4 to -11.1).23 While the study was not specific to the ADT-related fracture population, the results are likely relevant. Also, while no prospective studies have been developed to investigate the economic burden of ADT-related fractures in men with prostate cancer and no bone metastases, one recent retrospective claims database study evaluated healthcare system costs over a three-year period.24 In this study, ADT-treated prostate cancer patients who had experienced a fracture cost the healthcare system more than double ADT-naïve prostate cancer patients who had not experienced a fracture (adjusted costs using a multivariate general linear model: $29,044 versus $68,647).24
Types of Androgen-deprivation Therapy and Corresponding Bone Effects
Orchiectomy and gonadotropin-releasing hormone (GnRH) agonists (± an antiandrogen) are the most common modalities used to achieve androgen suppression in prostate cancer patients. Shortly after therapy initiation, either method causes an increase in markers of bone turnover and/or accelerated bone loss.13–16,18,20,25 Furthermore, orchiectomy and GnRH agonists (± an antiandrogen) increase the risk for fracture (see Table 1).10,12,14,16,17,19,20,25–31 The mechanism by which orchiectomy and GnRH agonists (± an antiandrogen) induce bone loss is directly related to the decrease of levels of both testosterone (by up to 95%) and estrogen (by up to 80%) achieved with these therapies.1

Bone remodeling is dependent on a balance of osteoblasts (bone formation cells) and osteoclasts (bone resorption cells); testosterone and estrogen play key roles in this balance.27 Testosterone stimulates osteoblast proliferation and inhibits osteoblast and osteoclast apoptosis; therefore, a deficiency in testosterone causes a decrease in the number of osteoblasts and osteoblast function.27 Estrogen is the primary hormone responsible for regulating bone resorption, and estrogen deficiencies Ketoconazole inhibits cytochrome P450 enzyme-induced synthesis of testosterone precursors and is sometimes used as second-line therapy when disease progression occurs after conventional ADT.30 Although studies that evaluate the bone effects of ketoconazole in prostate cancer patients are lacking, bone loss has been observed in renal transplantation patients receiving ketoconazole during the first six months post-transplant.34 Whether these results are solely a result of ketoconazole’s effect on calcitriol or due to its inhibition of the metabolism of corticosteroids that also have detrimental effects on bone is yet to be determined.34 Ongoing studies are evaluating the use of ketoconazole as ADT in patients who are unresponsive to conventional ADT, and ADT with GnRH antagonists is currently under investigation for use in prostate cancer patients who progress while receiving a GnRH agonist. If GnRH antagonists prove to prolong survival time (similar to GnRH agonists) and are found to be safe for use in these patients, studies evaluating bone effects of these agents will be needed; currently, GnRH antagonists are reserved for palliative therapy in patients with advanced symptomatic disease who are not candidates for GnRH agonists or refuse orchiectomy.30
Maintaining Bone Health and Integrity During Androgen-deprivation Therapy
Various factors, including baseline BMI <25kg/m2, hyperthyroidism, hyperparathyroidism, liver disease, and calcium or vitamin D malabsorption/ deficiencies, place prostate cancer patients at risk for bone loss even before ADT is initiated.7 Although studies to date have not been designed to show whether minimizing bone loss prevents fractures in prostate cancer patients without bone metastases, loss of BMD is a proven reliable surrogate marker for fracture risk.22 Therefore, all prostate cancer patients should be evaluated for underlying causes of bone loss, as well as counseled on the importance of lifestyle modifications (i.e. smoking cessation, minimizing alcohol consumption, routine weight-bearing exercise) and daily calcium (500–1,500mg) and vitamin D (400–800IU) supplementation to help prevent bone loss.1,3,35 Clinicians should consider pharmaceutical intervention (bisphosphonate therapy, estrogens, selective estrogen receptor modulators [SERMs]) for patients at greatest risk for bone loss, especially those receiving ADT. Furthermore, national guidelines now recommend that all patients receive a baseline BMD scan before beginning ADT.3 Routine follow-up BMD scans (every six to 12 months) should also be considered in patients receiving ADT.1
Bisphosphonates inhibit osteoclast activity.7 Both oral and intravenous (IV) formulations have demonstrated efficacy in preventing and, in the case of zoledronic acid, reversing bone loss (see Table 2).10,15–17,19,21,25,36–39 Intravenous bisphosphonate formulations are the most studied; however, recent results suggest that oral alendronate and risedronate maintain or significantly increase BMD in patients receiving ADT (see Table 2).10,15–17,19,21,25,36–39

Both of the IV bisphosphonates—pamidronate and zoledronic acid—have demonstrated efficacy in preventing bone loss in men with prostate cancer and no bone metastases receiving ADT (see Table 2).10,15–17,19 Pamidronate appears to maintain BMD during ADT, while several studies show that zoledronic acid increases BMD.10,15–17,19 Whether bisphosphonates prevent fractures in prostate cancer patients without bone metastases, as has been observed in patients with metastatic disease and in other cancer and noncancer populations at risk for bone loss, is unknown.1,40
While ongoing studies are evaluating the effect of bisphosphonates on fracture rate in prostate cancer patients without bone metastases, the National Comprehensive Cancer Network (NCCN) recommends that all prostate cancer patients with baseline osteopenia or osteoporosis receive bisphosphonate therapy while undergoing ADT.3 Whether patients with other osteoporotic risk factors (e.g. low BMI, inadequate vitamin D and/or calcium intake) at baseline should receive bisphosphonate therapy to prevent the development of osteopenia or osteoporosis is unknown. However, results of studies indicate that if initiated during the first year of ADT, when ADT-related bone loss is greatest, zoledronic acid prevents and often reverses bone loss in patients with a variety of risk factors.13,17

Bisphosphonates are generally well tolerated. Although serious AEs such as renal dysfunction and osteonecrosis of the jaw (ONJ) are rare in prostate cancer patients, clinicians should monitor their patients, especially men who are at the highest risk for developing them. In the case of zoledronic acid, grade 3 or 4 renal AEs appear to be related to the dose and infusion rate, and have not been observed in studies evaluating 4mg doses administered over 15 minutes.16,17,19 However, the dose may be adjusted for patients who are at risk for or with underlying renal dysfunction.41 ONJ with bisphosphonate treatment is most commonly reported in multiple myeloma and breast cancer patients.41 No cases of ONJ have been reported in clinical trials evaluating zoledronic acid (4mg q three months) in patients with prostate cancer without bone metastases.16,17,19 Patients who undergo dental procedures (e.g. tooth extraction) within one year prior to or during bisphosphonate therapy and/or are receiving chemotherapy or corticosteroid therapy are at a higher risk for ONJ.42 To avoid the requirement for dental procedures during bisphosphonate therapy, clinicians should counsel all bisphosphonate-therapy patients on the appear to play a larger role in the AEs of ADT than testosterone deficiencies.32 Estrogen deficiencies cause osteoclast activation, decrease osteoclast apoptosis, and possibly decrease osteoblast formation, proliferation, and function.27 Ultimately, the net result of this imbalance is bone loss. Although the greatest degree of bone loss tends to occur during the first year of ADT, the prevalence of osteopenia/osteoporosis appears to increase with prolonged duration of ADT.13,33 Results of one study found that after only two years of GnRH agonist (± bicalutamide) therapy, approximately 40% of bone-metastases-free prostate cancer patients developed osteoporosis; this rate doubled to approximately 80% after 10 years of therapy, and no patients had a normal BMD beyond 10 years.33 Fracture risk also appears to increase with the duration of ADT; however, studies evaluating the long-term incidence in patients without bone metastases are needed.4

Little is known about the extent to which other forms of ADT such as estrogen and antiandrogen monotherapy, intermittent GnRH agonists (± antiandrogen), GnRH antagonists, and ketoconazole affect bone health. However, results of studies indicate that some of the less conventional modalities may have less of a negative impact on BMD, and some may actually prevent bone loss (see Table 1).12,17,25,28,29 For example, Scherr and colleagues28 found that markers of bone resorption (N-telopeptide [NTX]) did not increase from baseline in prostate cancer patients receiving diethylstilbesterol (DES) monotherapy compared with controls; in contrast, NTX levels increased in men who had undergone an orchiectomy or were receiving GnRH monotherapy. Similarly, in another study evaluating the bone effects of antiandrogen (bicalutamide) monotherapy, NTX and deoxypyridinoline (biochemical markers of osteoclast activity) levels were significantly higher in men receiving a GnRH agonist compared with patients receiving bicalutamide monotherapy.29 Bone turnover marker levels were similar between the hormone-naïve and bicalutamide groups.29 These results suggest that antiandrogen monotherapy may prevent bone loss in men requiring long-term ADT, likely as a result of uninhibited estrogen activity. Larger studies to confirm these results are needed. BMD loss may also be minimized with intermittent GnRH agonist therapy, allowing for BMD stabilization to occur during the off-treatment period, although the long-term effects of intermittent ADT on BMD are unknown.12


  1. Higano CS, Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician, Urol Clin North Am, 2004;31:331–52.
  2. Jemal A, Siegel R,Ward E, et al., Cancer statistics 2008, CA Cancer J Clin, 2008;58:71–96.
  3. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V.1, 2008. Available at:
  4. Smith MR, Lee WC, Brandman J, et al., Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with non-metastatic prostate cancer, J Clin Oncol, 2005;23:7897–7903.
  5. Smith MR, Boyce SP, Moyneur E, et al., Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer, J Urol, 2006;175:136–9.
  6. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS, Risk of fracture after androgen deprivation for prostate cancer, N Engl J Med, 2005;352:154–64.
  7. Higano CS, Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?, Nat Clin Pract Urol, 2008;5:24–34.
  8. Braga-Basaria M, Dobs AS, Muller DC, et al., Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy, J Clin Oncol, 2006;24:3979–83.
  9. Chen Z, Maricic M, Nguyen P, et al., Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma, Cancer, 2002;95:2136–44.
  10. Michaelson MD, Kaufman DS, Lee H, et al., Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer, J Clin Oncol, 2007;25:1038–42.
  11. Lu-Yao G, Stukel TA, Yao SL, Changing patterns in competing causes of death in men with prostate cancer: a population based study, J Urol, 2004;171:2285–90.
  12. Higano C, Shields A,Wood N, et al., Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression, Urology, 2004;64: 1182–6.
  13. Greenspan SL, Coates P, Sereika SM, et al., Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer, J Clin Endocrinol Metab, 2005;90:6410–17.
  14. Maillefert JF, Sibilia J, Michel F, et al., Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma, J Urol, 1999;161:1219–22.
  15. Smith MR, McGovern FJ, Zietman AL, et al., Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer, N Engl J Med, 2001;345:948–55.
  16. Smith MR, Eastham J, Gleason DM, et al., Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer, J Urol, 2003;169:2008–12.
  17. Israeli RS, Rosenberg SJ, Saltzstein DR, et al., The effect of zoledronic acid on bone mineral density in patients undergoing androgen-deprivation therapy, Clin Genitourin Cancer, 2007;5: 271–7.
  18. Berruti A, Dogliotti L, Terrone C, et al., for the Gruppo Onco Urologico Piemontese (GOUP), Rete Oncologica Piemontese, Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy, J Urol, 2002;167:2361–7.
  19. Ryan CW, Huo D, Demers LM, et al., Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer, J Urol, 2006;176:972–8.
  20. Mittan D, Lee S, Miller E, et al., Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs, J Clin Endocrinol Metab, 2002;87:3656–61.
  21. Greenspan SL, Nelson JB, Trump DL, Resnick NM, Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial, Ann Intern Med, 2007;146:416–24.
  22. Schuit SC, van der Klift M,Weel AE, et al., Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study, Bone, 2004;34:195–202.
  23. Adachi JD, Loannidis G, Berger C, et al., The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada, Osteoporos. Int, 2001;12:903–8.
  24. Krupski TL, Foley KA, Baser O, et al., Healthcare cost associated with prostate cancer, androgen deprivation therapy and bone complications, J Urol, 2007;178:1423–8.
  25. Eriksson S, Eriksson A, Stege R, Carlstrom K, Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens, Calcif Tissue Int, 1995;57:97–9.
  26. Daniell HW, Dunn SR, Ferguson DW, et al., Progressive osteoporosis during androgen deprivation therapy for prostate cancer, J Urol, 2000;163:181–6.
  27. Riggs BL, Khosla S, Melton LJ III, Sex steroids and the construction and conservation of the adult skeleton, Endocr Rev, 2002;23: 279–302.
  28. Scherr D, Pitts WR Jr, Vaughn ED Jr, Diethylstilbestrol revisited: androgen deprivation, osteoporosis and prostate cancer, J Urol, 2002;167:535–8.
  29. Smith MR, Fallon MA, Goode MJ, Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer, Urology, 2003;61:127–31.
  30. Sharifi N, Gulley JL, Dahut WL, Androgen deprivation therapy for prostate cancer, JAMA, 2005;294:238–44.
  31. Oefelein MG, Resnick MI, The impact of osteoporosis in men treated for prostate cancer, Urol Clin North Am, 2004;31:313–19.
  32. Smith MR, Selective estrogen receptor modulators to prevent treatment-related osteoporosis, Rev Urol, 2005;(Suppl. 3):S30–35.
  33. Morote J, Morin JP, Orsola A, et al., Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer, Urology, 2007;69:500–504.
  34. Moore LW, Alloway RR, Acchiardo SR, et al., Clinical observations of metabolic changes occurring in renal transplant recipients receiving ketoconazole, Transplantation, 1996;61:537–41.
  35. Agarwal MM, Khandelwal N, Mandal AK, et al., Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy, Cancer, 2005;103:2042–52.
  36. Greenspan SL, Nelson JB, Trump DL, et al., Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy, J Clin Oncol, 2008;26:4426–34.
  37. Ishizaka K, Machinda T, Kobayasi S,et al., Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer, Int J Urol, 2007;12:1071–5.
  38. Smith MR, Fallon MA, Lee H, Finkelstein JS, Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial, J Clin Endocrinol Metab, 2004;89:3841–6.
  39. Smith MR, Malkowicz SB, Chu F, et al., Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study, J Urol, 2008;179:152–5.
  40. Black DM, Delmas PD, Eastell R, et al., Once-yearly zoledronic acid for treatment of postmenopausal osteoparosis, N Engl J Med, 2007;356:1809–22.
  41. Aapro M, Abrahamsson PA, Body JJ, et al., Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel, Ann Oncol, 2008;19:420–32.
  42. Walter C, Al-Nawas B, Grötz KA, et al., Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate, Eur Urol, 2008; Epub ahead of print.
  43. Ettinger B, Black DM, Mitlak BH, et al., for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a three-year randomized clinical trial, JAMA, 1999;282:637–45.

Further Resources

Share this Article
Related Content In Prostate Cancer
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72